RxSight (RXST) Shares Plunge 8.51% Amid CFO Exit and Legal Probe

The share price fell to its lowest level so far this month, with an intraday decline of 1.04% on January 10, 2026. RxSight (RXST) shares have now dropped 8.51% over three consecutive sessions, reflecting heightened investor concerns amid recent corporate developments.

The stock’s decline was driven by the unexpected resignation of Chief Financial Officer Shelley Thunen on December 22, 2025, and a concurrent securities fraud investigation launched by Pomerantz LLP. Thunen’s departure, coupled with earlier management reshuffles, signaled leadership instability, while the legal probe raised questions about governance and compliance. These events overshadowed earlier operational improvements, triggering a 9.98% single-day drop on December 23, 2025, and eroding investor confidence in the company’s recovery trajectory.

The combination of leadership transitions and legal scrutiny has created a volatile environment for RxSight. The CFO’s exit disrupted operational continuity, and the investigation threatens reputational and financial risks, including potential lawsuits or regulatory penalties. Analysts at BTIG noted the timing of these events highlights ongoing commercial challenges, delaying the company’s turnaround. For RxSight to stabilize its stock, it must address governance gaps, secure stable leadership, and demonstrate sustained operational progress. Failure to resolve these issues could prolong uncertainty and further depress investor sentiment.